Interim report 1 January – 31 March 2019
Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes the Interim report for the period 1 January – 31 March 2019. The interim report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.Reporting period January – March 2019 · Net sales amounted to 0 DKK (0). · Operating profit was -2.345m DKK (-695). · Cash and bank assets amounted to 5.281m DKK (870). · Result per share was DKK -0.16 (-0.07). · Solidity was 92% (66). Highlights during the period · Scandion Oncology signed contract with